ORSEGIVI Trademark

Trademark Overview


On Monday, June 16, 2025, a trademark application was filed for ORSEGIVI with the United States Patent and Trademark Office. The USPTO has given the ORSEGIVI trademark a serial number of 99236964. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, February 11, 2026. This trademark is owned by Pfizer Inc.. The ORSEGIVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, cachexia, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use
orsegivi

General Information


Serial Number99236964
Word MarkORSEGIVI
Filing DateMonday, June 16, 2025
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, February 11, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, cachexia, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 16, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192

Trademark Events


Event DateEvent Description
Monday, June 16, 2025NEW APPLICATION ENTERED
Monday, June 16, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 16, 2025APPLICATION FILING RECEIPT MAILED
Wednesday, October 22, 2025ASSIGNED TO EXAMINER
Tuesday, October 28, 2025NON-FINAL ACTION WRITTEN
Tuesday, October 28, 2025NON-FINAL ACTION E-MAILED
Tuesday, October 28, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 30, 2026TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, January 30, 2026ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, January 30, 2026TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 30, 2026TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, February 11, 2026ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, February 11, 2026ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND